Dragonfly Therapeutics, Inc.

Daniel Fallon

Asya Grinberg

Ann F Cheung

Gregory P Chang

Bianka Prinz

William Haney

Bradley M Lunde

Ronnie Wei

Steven O'Neil

Nicolai Wagtmann

Christopher Ryan Morgan

Zong Sean Juo

Mitchell Bigelow

Hemanta Baruah

Jinyan Du

Dhruv Kam Sethi

Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Proteins binding NKG2D, CD16 and a tumor-associated antigen

Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.

Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies. The multi-specific binding proteins comprise a CD33-binding domain, an NKG2D-binding domain and a CD16-binding domain.

Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use

Described herein are multispecific binding proteins that bind NKG2D receptor, CD16, and CLEC12A, pharmaceutical compositions comprising the multispecific binding proteins, and therapeutic methods useful for the treatment of cancer.

Proteins binding NKG2D, CD16 and CLEC12A

Growing community of inventors

Winchester, MA, United States of America

Daniel Fallon